Clinical Practice: Combination Antifungal Therapy for Mold Infections: Much Ado about Nothing?
Open Access
- 15 June 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 46 (12) , 1889-1901
Abstract
In general, mortality rates associated with systemic fungal infections have not improved much in more than a decade, although the number of antifungal agents available for the treatment of serious fungal infections has increased in the past few years. A possible approach to decreasing mortality rates associated with fungal infections may be to treat patients with combinations of different classes of antifungals. Recently, in vitro and animal studies evaluating different combinations of antifungal agents have demonstrated important synergistic and/or additive activity against many genera of fungi. However, prudence is required, because some antifungal combinations have demonstrated antagonistic activity. Well-controlled clinical trials are still necessary to define the most efficacious antifungal combination. In addition, these clinical trials should evaluate the adverse event profile of the combination regimens, as well as their pharmacoeconomic impact.Keywords
This publication has 83 references indexed in Scilit:
- The concentration-dependent nature of in vitro amphotericin B–itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactionsInternational Journal of Antimicrobial Agents, 2006
- Echinocandin antifungals: review and updateExpert Review of Anti-infective Therapy, 2006
- The Changing Face of Fungal Infections in Health Care SettingsClinical Infectious Diseases, 2005
- Combination Treatment of Invasive Fungal InfectionsClinical Microbiology Reviews, 2005
- Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infectionsInternational Journal Of Clinical Practice, 2004
- In Vitro Interactions between Amphotericin B, Itraconazole, and Flucytosine against 21 Clinical Aspergillus Isolates Determined by Two Drug Interaction ModelsAntimicrobial Agents and Chemotherapy, 2004
- Combination Antifungal TherapyAntimicrobial Agents and Chemotherapy, 2004
- Comparison of Fractional Inhibitory Concentration Index with Response Surface Modeling for Characterization of In Vitro Interaction of Antifungals against Itraconazole-Susceptible and -ResistantAspergillus fumigatusIsolatesAntimicrobial Agents and Chemotherapy, 2002
- Effect of sequential combination of amphotericin B and azole antifungal agents against Aspergillus fumigatusJournal of Infection and Chemotherapy, 1999
- A Method for Testing for Synergy with Any Number of AgentsThe Journal of Infectious Diseases, 1978